<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Subst Abuse Rehabil</journal-id><journal-id journal-id-type="iso-abbrev">Subst Abuse Rehabil</journal-id><journal-id journal-id-type="pmc-domain-id">2178</journal-id><journal-id journal-id-type="pmc-domain">sar</journal-id><journal-id journal-id-type="publisher-id">sar</journal-id><journal-title-group><journal-title>Substance Abuse and Rehabilitation</journal-title></journal-title-group><issn pub-type="epub">1179-8467</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11016949</article-id><article-id pub-id-type="pmcid-ver">PMC11016949.1</article-id><article-id pub-id-type="pmcaid">11016949</article-id><article-id pub-id-type="pmcaiid">11016949</article-id><article-id pub-id-type="pmid">38623317</article-id><article-id pub-id-type="doi">10.2147/SAR.S433358</article-id><article-id pub-id-type="publisher-id">433358</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Managing Opioid Withdrawal Symptoms During the Fentanyl Crisis: A Review</article-title><alt-title alt-title-type="running-authors">Weber et al</alt-title><alt-title alt-title-type="running-title">Weber et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7124-776X</contrib-id><name name-style="western"><surname>Weber</surname><given-names initials="AN">Andrea Nicole</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8322-2500</contrib-id><name name-style="western"><surname>Trebach</surname><given-names initials="J">Joshua</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1837-6105</contrib-id><name name-style="western"><surname>Brenner</surname><given-names initials="MA">Marielle A</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thomas</surname><given-names initials="MM">Mary Margaret</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8847-8727</contrib-id><name name-style="western"><surname>Bormann</surname><given-names initials="NL">Nicholas L</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><aff id="aff0001"><label>1</label><institution>Department of Psychiatry, University of Iowa</institution>, <addr-line>Iowa City</addr-line>, <addr-line>IA</addr-line>, <country>USA</country></aff><aff id="aff0002"><label>2</label><institution>Department of Emergency Medicine, University of Iowa</institution>, <addr-line>Iowa City</addr-line>, <addr-line>IA</addr-line>, <country>USA</country></aff><aff id="aff0003"><label>3</label><institution>Hardin Library for the Health Sciences, University of Iowa</institution>, <addr-line>Iowa City</addr-line>, <addr-line>IA</addr-line>, <country>USA</country></aff><aff id="aff0004"><label>4</label><institution>Department of Psychiatry and Psychology, Mayo Clinic</institution>, <addr-line>Rochester</addr-line>, <addr-line>MN</addr-line>, <country>USA</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Andrea Nicole Weber, Department of Psychiatry, University of Iowa, <addr-line>500 Newton Road, 1-308 MEB</addr-line>, <addr-line>Iowa City</addr-line>, <addr-line>IA</addr-line>, <addr-line>52242</addr-line>, <country>USA</country>, <phone content-type="general">Tel +1-319-335-6980</phone>, <fax>Fax +1-319-384-7467</fax>, Email andrea-n-weber@uiowa.edu</corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">452758</issue-id><fpage>59</fpage><lpage>71</lpage><history><date date-type="received"><day>07</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>05</day><month>4</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>15</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-24 20:25:32.927"><day>24</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 Weber et al.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Weber et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v3.0) License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="sar-15-59.pdf"/><abstract><title>Abstract</title><p>Illicitly manufactured fentanyl (IMF) is a significant contributor to the increasing rates of overdose-related deaths. Its high potency and lipophilicity can complicate opioid withdrawal syndromes (OWS) and the subsequent management of opioid use disorder (OUD). This scoping review aimed to collate the current OWS management of study populations seeking treatment for OWS and/or OUD directly from an unregulated opioid supply, such as IMF. Therefore, the focus was on therapeutic interventions published between January 2010 and November 2023, overlapping with the period of increasing IMF exposure. A health science librarian conducted a systematic search on November 13, 2023. A total of 426 studies were screened, and 173 studies were reviewed at the full-text level. Forty-nine studies met the inclusion criteria. Buprenorphine and naltrexone were included in most studies with the goal of transitioning to a long-acting injectable version. Various augmenting agents were tested (buspirone, memantine, suvorexant, gabapentin, and pregabalin); however, the liberal use of adjunctive medication and shortened timelines to initiation had the most consistently positive results. Outside of FDA-approved medications for OUD, lofexidine, gabapentin, and suvorexant have limited evidence for augmenting opioid agonist initiation. Trials often have low retention rates, particularly when opioid agonist washout is required. Neurostimulation strategies were promising; however, they were developed and studied early. Precipitated withdrawal is a concern; however, the rates were low and adequately mitigated or managed with low- or high-dose buprenorphine induction. Maintenance treatment continues to be superior to detoxification without continued management. Shorter induction protocols allow patients to initiate evidence-based treatment more quickly, reducing the use of illicit or non-prescribed substances.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>synthetic opioids</kwd><kwd>treatment</kwd><kwd>diagnosis</kwd><kwd>prevention</kwd><kwd>addiction medicine</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><ref-count count="100"/><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Despite policy changes targeting improved access and availability of opioid use disorder (OUD) treatment, opioid-related overdose deaths continue to increase in the United States. Between June 2022 and 2023, the Center for Disease Control and Prevention reported 106,661 drug overdose deaths, a 2.3% increase from the 12-months prior.<xref rid="cit0001" ref-type="bibr">1</xref> Beginning around 2013, opioid overdose deaths previously associated with prescription opioids and heroin were superseded by deaths associated with non-methadone synthetic opioids, including illicitly manufactured fentanyl (IMF) and its analogues.<xref rid="cit0002" ref-type="bibr">2</xref> IMF exposure can be unintentional at both the individual and systemic levels. Individuals may use stimulants or other opioids that unknowingly contain IMF.<xref rid="cit0003" ref-type="bibr">3</xref> At a systemic level, contamination during the manufacturing or distribution process can increase exposure risk over large geographic areas.<xref rid="cit0003" ref-type="bibr">3</xref> Fentanyl&#8217;s high potency and lipophilicity can complicate opioid withdrawal syndromes (OWS) and OUD management, which increases the urgency for more effective and accessible OWS treatments.<xref rid="cit0004" ref-type="bibr">4</xref></p><sec id="s0001-s2001"><title>Current State of Opioid Withdrawal</title><p>The endogenous opioid receptor system consists of four primary G-protein coupled receptors, including mu, delta, kappa, and opioid receptor-like 1.<xref rid="cit0005" ref-type="bibr">5</xref> Opioid receptors exist throughout the nervous system and are expressed by most major organs.<xref rid="cit0006" ref-type="bibr">6</xref> Both endogenous and exogenous ligands interact with these receptors. The effect of receptor agonism is a function of ligand, receptor type, and location.<xref rid="cit0007" ref-type="bibr">7</xref> The opioid system is required for normal reward- and aversion-based learning. When compromised, the integration of reward and pain aversion information is impaired, as observed in OUD.</p><p>Exogenous opioid potency has been positively correlated with mu-opioid receptor desensitization and cyclic adenosine monophosphate upregulation. These changes are hypothesized to mediate increased OWS severity secondary to IMF exposure.<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0009" ref-type="bibr">9</xref></p></sec><sec id="s0001-s2002"><title>Identifying Opioid Withdrawal</title><p>OWS occur following the cessation or significant decrease in opioid receptor activity after weeks to months of agonism.<xref rid="cit0010" ref-type="bibr">10</xref> Opioid tolerance, physical dependence, and/or withdrawal do not equate with OUD, but many with OUD experience these physiologic adaptations.<xref rid="cit0011" ref-type="bibr">11</xref> OWS include physical and psychological symptoms, including chills, body aches, emesis, diarrhea, dysphoria, irritability, and anxiety.<xref rid="cit0012" ref-type="bibr">12</xref> Several validated tools exist to facilitate diagnosing and rating OWS severity. The Clinical Opiate Withdrawal Scale (COWS), published in 1999, is widely used in clinical care and research. Symptoms were categorized by severity or intensity (eg, reported nausea being of low severity and observable emesis being of high severity). Total score correlates with OWS severity and is categorized into severity groups.<xref rid="cit0013" ref-type="bibr">13</xref> The Subjective Opiate Withdrawal Scale (SOWS) and Objective Opiate Withdrawal Scale (OOWS) also exist for use.<xref rid="cit0014" ref-type="bibr">14</xref> The SOWS is distinct as patients rate 16 items from a score of &#8220;not at all&#8221; to &#8220;extremely&#8221; (0 to 4). Items include &#8220;I feel anxious&#8221; and &#8220;My muscles twitch.&#8221; In contrast, OOWS is observer-rated, noting the presence and/or frequency of 13 signs of opioid withdrawal including yawning, mydriasis, and restlessness.</p></sec><sec id="s0001-s2003"><title>Opioid Withdrawal Treatment</title><p>Efficient OWS identification, assessment, and treatment are crucial. Symptom resolution, by either treatment or return to use, is an important motivator in OUD.<xref rid="cit0012" ref-type="bibr">12</xref> Fear of opioid withdrawal, particularly its undertreatment in the healthcare setting, has been a frequently reported reason for individuals delaying OUD treatment.<xref rid="cit0015" ref-type="bibr">15</xref> Individuals with OUD may discontinue hospitalization or medical care following inadequately treated withdrawal and pain.<xref rid="cit0016" ref-type="bibr">16</xref>,<xref rid="cit0017" ref-type="bibr">17</xref> For example, approximately 1 in 6 people hospitalized for drug use-associated infective endocarditis leave the hospital prematurely due to undertreated withdrawal.<xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0019" ref-type="bibr">19</xref></p><p>The use of methadone, buprenorphine, and other full-agonist opioids to treat OWS is the standard of care.<xref rid="cit0020" ref-type="bibr">20</xref> Both buprenorphine and methadone as maintenance medications are effective in treatment retention and reducing illicit opioid use; this has continued support in the fentanyl era.<xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0022" ref-type="bibr">22</xref> Yet, growing evidence suggests OWS following IMF does not respond as well to non-opioid medications, buprenorphine, introductory doses of methadone, or standard doses of slow-release oral morphine.<xref rid="cit0023" ref-type="bibr">23&#8211;25</xref> Given the risk of returning to opioid use and overdose death when these medications are only utilized for short-term withdrawal management, published guidelines highlight the importance of maintenance of MOUD.<xref rid="cit0026" ref-type="bibr">26</xref></p></sec></sec><sec id="s0002"><title>Aim</title><p>We reviewed current practices in OWS management and presented therapeutic interventions that have been studied and published between January 2010 and November 2023, focusing on research that may inform OWS management while increasing IMF exposure. This review focuses specifically on study populations seeking treatment for OWS and/or OUD directly from an unregulated opioid supply such as IMF.</p></sec><sec id="s0003"><title>Methods</title><p>The search strategies were developed in collaboration with a health science librarian (MT). Searches focused on identifying citations of opioid withdrawal concepts.</p><p>Systematic search strategies were created for PubMed and PsycINFO (EBSCOhost) databases. The search terms included controlled vocabulary, synonyms, and concepts related to opiates, opioid withdrawal, and opioid withdrawal management. The final database search was conducted on November 13, 2023, with all results exported to a citation manager the same day. Date of publication was limited to between January 2010 and November 2023. The January 2010 start date was considered a conservative time estimate for when IMF was entering the drug supply, but prior to the surge in IMF-related overdose deaths.<xref rid="cit0027" ref-type="bibr">27</xref></p><p>In addition to date filters in both databases, PubMed&#8217;s clinical study filter and PsycINFO&#8217;s age and academic journal filters were used. Inclusion criteria were adults (18 years old and older) most recently utilizing an illicit, unregulated drug supply prior to the identification and/or treatment of opioid withdrawal. Exclusion criteria included studies on neonatal withdrawal syndromes or transitioning from a regulated and/or prescription opioid supply.</p><p>After deduplication, 426 studies were included. Article titles and abstracts were screened by AW and NB, using the inclusion and exclusion criteria described above. AW, JT, MB, and NB reviewed the full text of the articles and 173 studies. Uncertainty was resolved by discussion of AW, JT, MB, and NB as needed. <xref rid="f0001" ref-type="fig">Figure 1</xref> summarizes the PRISMA flowchart for study inclusion.</p></sec><sec id="s0004"><title>Results</title><sec id="s0004-s2001"><title>Buprenorphine</title><p>Buprenorphine is a partial agonist of the mu-opioid receptor with high receptor affinity.<xref rid="cit0028" ref-type="bibr">28</xref> This characteristic allows for the displacement of full agonists by buprenorphine, causing buprenorphine-precipitated opioid withdrawal (BPOW). BPOW typically develops within 10&#8211;15 minutes following buprenorphine administration, lasts 8&#8211;24 hours and has been objectively defined by some as an increase of &gt;6 on the COWS<xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0030" ref-type="bibr">30</xref> Notably, chronic IMF use carries a greater risk of BPOW.<xref rid="cit0031" ref-type="bibr">31</xref> Prior to the rise of IMF, BPOW was estimated to occur in 9% of buprenorphine initiations.<xref rid="cit0030" ref-type="bibr">30</xref> This risk has subsequently increased with traditional initiation models, likely secondary to fentanyl&#8217;s rapid onset of action and high lipophilicity<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0032" ref-type="bibr">32</xref> For a standard buprenorphine induction in those chronically exposed to fentanyl, some guidelines suggest that waiting until the COWS is &gt;13 (moderate severity range).<xref rid="cit0033" ref-type="bibr">33</xref> However, low-dose and high-dose initiations are alternative options.</p><p>Review results indicate that buprenorphine continues to be effective for OWS treatment.<xref rid="cit0034" ref-type="bibr">34</xref> Notably, buprenorphine maintenance treatment remains superior to detoxification alone in reducing illicit opioid use and increasing treatment retention.<xref rid="cit0022" ref-type="bibr">22</xref> Therefore, it is of high importance to have effective approaches to initiate buprenorphine in the fentanyl era. One method is low-dose initiation (ie, microinduction), which provides increased flexibility as it can be initiated at any COWS level but requires access to full-agonist opioids throughout the titration.<xref rid="cit0035" ref-type="bibr">35</xref> It is premised on slowly increasing the buprenorphine dose and frequency over several days, while a full-agonist opioid is maintained. This avoids prolonged moderate-to-severe OWS while minimizing clinically significant BPOW risk.<xref rid="cit0036" ref-type="bibr">36</xref> Low-dose initiations can be adapted for various formulations of buprenorphine, including intravenous, transdermal, and buccal versions.<xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0038" ref-type="bibr">38</xref> An example of a low-dose buprenorphine initiation using a full-agonist opioid to bridge is included in <xref rid="t0001" ref-type="table">Table 1</xref>. Other studies have also examined low-dose buprenorphine initiation protocols that may not require full agonist&#8211;opioid bridging. For example, a 20 mcg/h transdermal patch can be used for the initial 24&#8211;48 hours, with 8 and 16 mg sublingual buprenorphine administered at the 24 and 48 h mark, respectively. On day 3, the transdermal patch was removed and followed by sublingual buprenorphine titration. Most patients evaluated retrospectively with this method were reported to tolerate it fairly well.<xref rid="cit0037" ref-type="bibr">37</xref> This protocol is summarized in <xref rid="t0002" ref-type="table">Table 2</xref>.
<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1</label><caption><p>Low-Dose Buprenorphine Initiation Using Sublingual Buprenorphine</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Day</th><th rowspan="1" colspan="1">Sublingual Buprenorphine</th><th rowspan="1" colspan="1">Full-Agonist Opioids</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.5 mg QD</td><td rowspan="1" colspan="1">Continue</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0.5 mg BID</td><td rowspan="1" colspan="1">Continue</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1 mg BID</td><td rowspan="1" colspan="1">Continue</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2 mg BID</td><td rowspan="1" colspan="1">Continue</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">4 mg BID</td><td rowspan="1" colspan="1">Continue</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">4 mg TID</td><td rowspan="1" colspan="1">Continue</td></tr><tr><td rowspan="1" colspan="1">7+</td><td rowspan="1" colspan="1">8 mg BID</td><td rowspan="1" colspan="1">STOP</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Note</bold>: Data from Cohen et al<xref rid="cit0036" ref-type="bibr">36</xref></p></fn><fn id="tfn0002"><p><bold>Abbreviations</bold>: QD, once per day; BID, twice per day; TID, three times per day; +, and following days.</p></fn></table-wrap-foot></table-wrap>
<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2</label><caption><p>Low-Dose Buprenorphine Initiation Using Transdermal Buprenorphine Without Concurrent Full-Agonist Opioid</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Day</th><th rowspan="1" colspan="1">Transdermal Buprenorphine</th><th rowspan="1" colspan="1">Sublingual Buprenorphine</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">20 mcg/hr</td><td rowspan="1" colspan="1">&#8211;</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">20 mcg/hr</td><td rowspan="1" colspan="1">8 mg QD or BID</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">8 mg BID, up-titrate as needed</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p><bold>Note</bold>: Data from Baumgartner et al<xref rid="cit0037" ref-type="bibr">37</xref></p></fn><fn id="tfn0004"><p><bold>Abbreviations</bold>: mcg/hr, micrograms per hour; QD, once per day; BID, twice per day.</p></fn></table-wrap-foot></table-wrap></p><p>The initiation of high-dose buprenorphine therapy is another treatment strategy. It is predicated on rapidly reaching therapeutic buprenorphine levels by repeatedly dosing 8&#8211;24 mg of buprenorphine every 30&#8211;60 minutes until OWS has resolved followed by subsequent daily maintenance of buprenorphine.<xref rid="cit0039" ref-type="bibr">39</xref> This technique was primarily developed and studied in emergency department settings, where rapid stabilization and discharge are a priority.<xref rid="cit0039" ref-type="bibr">39</xref> Extended release buprenorphine (BUP-XR) formulations (ie, injectables) have been similarly utilized in the emergency department without precipitating opioid withdrawal.<xref rid="cit0040" ref-type="bibr">40</xref> An observational cohort of 1200 people with fentanyl-positive urine receiving emergency department-initiated buprenorphine reported only 9 episodes of precipitated withdrawal. These were equally distributed between sublingual and BUP-XR formulations.<xref rid="cit0041" ref-type="bibr">41</xref></p><p>High-dose regimens, along with adjunctive medication, are increasingly used for BPOW treatment.<xref rid="cit0033" ref-type="bibr">33</xref>,<xref rid="cit0039" ref-type="bibr">39</xref> A case documented BPOW (COWS 16 increased to 33) after the administration of buprenorphine 8 mg following 29 h of no illicit substance use. Escalated doses of buprenorphine 4&#8211;16 mg every 2&#8211;3 hours were administered over the next 24 hours, reducing the COWS to a 5.<xref rid="cit0028" ref-type="bibr">28</xref> A similar case of BPOW used repeated 16 mg dosing of buprenorphine, totaling 148 mg over the first 48 hours, to adequately treat symptoms.<xref rid="cit0032" ref-type="bibr">32</xref> Additionally, higher buprenorphine doses may provide greater reductions in COWS and cravings.<xref rid="cit0042" ref-type="bibr">42</xref> This data emphasizes the need for dosing flexibility when managing OWS, particularly BPOW.</p><p>Strategies also exist to accelerate the transition from illicit opioids to BUP-XR. Mariani et al transitioned 5 patients from high-potency opioids to BUP-XR after only 2&#8211;3 days of sublingual buprenorphine. This was 4&#8211;5 days faster than that of the package insert. The induction COWS ranged between 10 and 16, with a day 1 sublingual buprenorphine dose range of 10&#8211;24 mg. In all cases, the COWS score was significantly reduced immediately and 24 h after treatment with 300 mg of BUP-XR. The authors concluded that tolerance to 16 mg sublingual buprenorphine over two days conferred successful transition to BUP-XR and that further delay was unnecessary.<xref rid="cit0043" ref-type="bibr">43</xref> Another strategy involved one dose of 4 mg sublingual buprenorphine followed an hour later by BUP-XR 300 mg if COWS did not increase by 6 or more following the sublingual dose. BPOW did not occur following any sublingual buprenorphine and only occurred in 2 (8.3%) cases following BUP-XR. Notably, both patients had the highest urine fentanyl and norfentanyl levels at the time of admission. The authors reported widespread use of adjuvant medications (ondansetron, clonidine, ibuprofen, and trazodone) in these patients.<xref rid="cit0040" ref-type="bibr">40</xref></p></sec><sec id="s0004-s2002"><title>Methadone</title><p>Methadone, a long-acting synthetic opioid with a full mu-opioid receptor agonist effect, has drawn increasing attention as a treatment for OWS and MOUD in the fentanyl era. Unlike buprenorphine, there is no risk of precipitating opioid withdrawal, increasing usability across settings.<xref rid="cit0044" ref-type="bibr">44</xref> Methadone serum concentrations have been inversely correlated with subjective OWS during initiation and maintenance phase, supporting dose adjustments based on patient reported cravings and withdrawal symptoms.<xref rid="cit0045" ref-type="bibr">45</xref> Methadone&#8217;s full agonist mechanism may provide additional benefit in cases where buprenorphine is unable to manage OWS.<xref rid="cit0046" ref-type="bibr">46</xref> In efforts to increase access to methadone, clinics are leveraging the &#8220;72 hour rule&#8221; under the current federal law, 21 CFR 1306.07, to more rapidly initiate methadone by non-opioid treatment program (OTP) providers and facilitate entry into OTPs. A transitional clinic in the Northeast United States working with a primarily fentanyl-exposed population (85%) successfully linked most individuals to an OTP (n = 138, 87%), with the majority (58%) still undergoing treatment at 1-month follow-up.<xref rid="cit0047" ref-type="bibr">47</xref></p><p>Methadone deregulation of OUD treatment in the United States to a community pharmacy-based distribution model resembling Canada and Australia has potential for increasing treatment retention and cost-effectiveness when compared to take-home flexible dosing buprenorphine.<xref rid="cit0048" ref-type="bibr">48</xref>,<xref rid="cit0049" ref-type="bibr">49</xref> The United States Congress is considering the Modernizing Opioid Treatment Access Act, which would allow physicians board-certified in addiction medicine or addiction psychiatry to prescribe methadone for OUD outside of OTP settings.<xref rid="cit0050" ref-type="bibr">50</xref> Critics raise concerns that this law could increase diversion and overdose risk while decreasing treatment retention.<xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0052" ref-type="bibr">52</xref> Supporters note the lack of OTP access in the United States and the significant burden OTP requirements place on patients.<xref rid="cit0053" ref-type="bibr">53</xref> Methadone take-home dosing relaxation during the COVID-19 pandemic was not associated with an increase in diversion or methadone-related overdose.<xref rid="cit0054" ref-type="bibr">54</xref>,<xref rid="cit0055" ref-type="bibr">55</xref> Given the increases in patient satisfaction and treatment engagement without significantly worsening outcomes, the above legislation continues to gain bipartisan support as opioid-related fatalities increase nationwide.<xref rid="cit0056" ref-type="bibr">56</xref></p></sec><sec id="s0004-s2003"><title>Other Opioid Agonist Treatments</title><p>Other full agonist opioids may be options for OUD treatment initiation and maintenance in the fentanyl era. A group in Vancouver, Canada, is studying sustained-release oral morphine (SROM) versus methadone in decreasing unregulated opioid use and improving treatment retention, safety, overdose risk, patient satisfaction, and quality of life.<xref rid="cit0057" ref-type="bibr">57</xref> This may add to the existing literature suggesting SROM has similar efficacy to methadone in increasing drug-free time.<xref rid="cit0058" ref-type="bibr">58</xref> In Iran, a study reviewing tramadol 600 mg daily vs methadone 60 mg daily to manage OWS over 3 days resulted in similar OOWS scores and drop-out rates.<xref rid="cit0059" ref-type="bibr">59</xref> Of note, conversion of tramadol to its highly potent active metabolite, O-desmethyltramadol, is dependent on CYP2D6 enzyme activity. The prevalence of CYP2D6 ultra-metabolizers (who create higher levels of O-desmethyltramadol) varies worldwide and is higher in Middle East populations.<xref rid="cit0060" ref-type="bibr">60</xref> Therefore, the use of tramadol for OWS management may not be generalizable.</p><p>Of note, the use of short-acting opioids to manage OWS in the United States during the fentanyl era has been limited to the hospital setting, given federal law restricting the use of full-agonist opioids to treat OUD outside of a federally certified OTP.<xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0062" ref-type="bibr">62</xref></p></sec><sec id="s0004-s2004"><title>Naltrexone/Naloxone</title><p>Naltrexone, an antagonist of the mu-opioid receptor, is an FDA-approved daily maintenance treatment for OUD. A once-monthly extended-release naltrexone (XR-NTX) intramuscular version is also available. A barrier to naltrexone initiation is the package insert requirement of 7&#8211;10 days being opioid free before initiation to avoid precipitated withdrawal. As discussed above, IMF&#8217;s properties heighten this concern.<xref rid="cit0004" ref-type="bibr">4</xref> Safe and comfortable inductions onto XR-NTX are particularly relevant as when looking at 24-week outcomes between initiation on either buprenorphine or XR-NTX, individuals have greater success starting buprenorphine; however, those who successfully start XR-NTX may do equally well at follow-up.<xref rid="cit0063" ref-type="bibr">63</xref></p><p>Several strategies have been developed to assist in initiation. All identified trials included liberal use of adjunctive medications (including clonidine, trazodone, acetaminophen, loperamide, clonazepam, zolpidem, or simply stating &#8220;and other adjuvant medications&#8221;). Rudolf et al highlighted how non-opioid-based withdrawal management (scheduled tizanidine, gabapentin, and hydroxyzine over four days) can be effective for some attempting to initiate XR-NTX.<xref rid="cit0064" ref-type="bibr">64</xref> However, the utilization of short-course buprenorphine was most common in the included literature.</p><p>Mannelli et al conducted two open-label trials to transition outpatients from illicit opioids to XR-NTX. In their initial trial, 20 patients using opioids (majority heroin) were started on 0.25 mg of naltrexone on day 1 along with 4 mg of buprenorphine. Naltrexone was titrated daily for 7 days to a final mean dose of 31.3 (SD = 8.14, range = 13&#8211;50); buprenorphine was decreased to 2 mg on days 2 and 3 and then discontinued. Fifteen of the 20 patients completed this phase. Fourteen patients received XR-NTX on day 8. The COWS peaked at baseline, decreased, and remained low throughout the 4-week follow-up period. Of interest, they note that increasing doses of naltrexone following discontinuation of buprenorphine had no significant changes on COWS.<xref rid="cit0065" ref-type="bibr">65</xref> Their second trial used the same buprenorphine 3-day taper and naltrexone escalation in a group of 35 patients, showing similar results.<xref rid="cit0066" ref-type="bibr">66</xref>
<xref rid="t0003" ref-type="table">Table 3</xref> summarizes protocols by Rudolf et al and Mannelli et al
<table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3</label><caption><p>Comparison of Published Protocols Using Various Medications to Transition to Extended-Release Naltrexone (XR-NTX)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Rudolf et al<xref rid="cit0064" ref-type="bibr">64</xref></th><th rowspan="1" colspan="1"/><th colspan="2" rowspan="1">Mannelli et al<xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0066" ref-type="bibr">66</xref></th></tr><tr><th rowspan="1" colspan="1">Medication (Max Daily mg)</th><th rowspan="1" colspan="1">DAY</th><th rowspan="1" colspan="1">Oral Naltrexone</th><th rowspan="1" colspan="1">Sublingual Buprenorphine</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">Tizanidine (32 mg) Hydroxyzine (600 mg) Gabapentin (1500 mg)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.25&#8211;0.5 mg</td><td rowspan="1" colspan="1">4 mg</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0.25&#8211;0.5 mg</td><td rowspan="1" colspan="1">2 mg</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0.5&#8211;1 mg</td><td rowspan="1" colspan="1">2 mg</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2&#8211;6 mg</td><td rowspan="1" colspan="1">&#8211;</td></tr><tr><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">3&#8211;15 mg</td><td rowspan="1" colspan="1">&#8211;</td></tr><tr><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">5&#8211;35 mg</td><td rowspan="1" colspan="1">&#8211;</td></tr><tr><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">13-50</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">XR-NTX</td><td rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="tfn0005"><p><bold>Notes</bold>: All protocols included other ancillary medications, such as dicyclomine, acetaminophen, naproxen, and loperamide.</p></fn><fn id="tfn0006"><p><bold>Abbreviations</bold>: mg, milligram; et al, et alia.</p></fn></table-wrap-foot></table-wrap>
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>Prisma Flow Diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="print-only" position="float" orientation="portrait" xlink:href="SAR-15-59-g0001.jpg"/></fig></p><p>Two trials compared naltrexone with naltrexone plus buprenorphine targeting XR-NTX initiation. Sullivan et al enrolled 150 patients with OUD who received adjunctive medications on day 1 and up to 8 mg buprenorphine on day 2. The study then diverged to either a washout day followed by increasing naltrexone doses (1 mg to 25 mg) on days 4&#8211;7 followed by XR-NTX on day 8 or a buprenorphine taper from 6 mg on day 3 to 1 mg on day 7, followed by a 7-day wash-out and XR-NTX on day 15. The OWS was comparable across groups; however, most participants complained of protracted OWS over the first 21 days. The naltrexone arm was significantly more likely to start XR-NTX (56.1% vs 32.7%) and receive a second injection (50.0% vs 26.9%). The authors concluded that the naltrexone arm benefited from shorter time-to-initiation.<xref rid="cit0067" ref-type="bibr">67</xref></p><p>Bisaga et al enrolled 378 patients with OUD with the goal of starting XR-NTX, randomized to 3 arms: naltrexone with buprenorphine, naltrexone with placebo buprenorphine, and placebo naltrexone with placebo buprenorphine. Naltrexone dosing began on day 1 at 0.25 mg and increased to 15 mg by day 7; buprenorphine dosing started at 4&#8211;6 mg on day 1, followed by 2 mg on days 2&#8211;3, and then wash-out. The COWS scores decreased similarly across the groups. Notably, SOWS was significantly lower in the naltrexone with buprenorphine arm after the day 8 XR-NTX injection than in the other arms. There was no difference between the groups in starting XR-NTX, with all arms below 50%.<xref rid="cit0068" ref-type="bibr">68</xref></p><p>Methods that eliminate multiple-day tapers include ultra-rapid opioid detoxification. However, little research has been conducted in this area. A review found one prospective study of 173 participants with physiological opioid dependence who underwent the ultra-rapid procedure.<xref rid="cit0069" ref-type="bibr">69</xref> Participants were premedicated with clonidine and midazolam, intubated using propofol and atracurium, and mechanically ventilated. Opioid detoxification occurred following 50 mg of naltrexone via a nasogastric tube, followed by intravenous naloxone for 6 h. The patient was then brought out of anesthesia. The mean OOWS was 1.52 before the procedure and peaked at 3.89 one hour after the end of anesthesia. They noted that participants experienced a high rate of withdrawal from the queried symptoms. No major adverse events were reported.</p><p>Bisaga et al conducted two trials with memantine augmentation of a buprenorphine taper onto naltrexone and XR-NTX.<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0071" ref-type="bibr">71</xref> Memantine is a glutamate antagonist at the N-methyl-d-aspartate (NMDA) receptor, with preclinical evidence that it ameliorates OWS. However, neither trial was found to be effective. Similarly, dronabinol, an oral synthetic molecule of delta-9-tetrahydrocannabinol, and lorcaserin, a high-affinity 5-HT2C receptor agonist, were investigated for the augmentation of buprenorphine tapers to start XR-NTX. Both trials yielded negative results.</p></sec><sec id="s0004-s2005"><title>Non-Opioid Pharmaceutical Treatments</title><p>Lofexidine is an alpha-2-adrenergic receptor agonist FDA-approved for management of OWS. In a pivotal trial, patients with OUD were randomized to receive 3.2 mg lofexidine daily for 5 days (n = 134) or placebo (n = 130). Overall retention was low, with 50 and 35 patients in the lofexidine and placebo groups, respectively, completing the 7-day inpatient detoxification period. The day 3 SOWS (primary endpoint) was significantly lower in the lofexidine group than in the placebo (6.32 vs 8.67, p = 0.021). Additionally, non-completers stayed in the trial longer if they received lofexidine.<xref rid="cit0072" ref-type="bibr">72</xref> Two different daily doses of lofexidine (2.16 mg and 2.88 mg) were compared against placebo in a trial of 603 patients with OUD over 7 days. Retention was low, at 27.8% for placebo, 41.5% for low-dose lofexidine, and 39.6% for high-dose lofexidine. However, both groups&#8217; SOWS were significantly lower than placebo, and few discontinuations were reported to be due to adverse side effects.<xref rid="cit0073" ref-type="bibr">73</xref> In a trial comparing lofexidine with diazepam, no differences were seen in OOWS or SOWS on days 3 and 4 (peak withdrawal).<xref rid="cit0074" ref-type="bibr">74</xref></p><p>Gabapentin and pregabalin, both N-type calcium channel blockers, have been studied for opioid withdrawal, typically as augmentation of opioid agonists. In a small placebo-controlled study, gabapentin augmentation (1600 mg daily) during buprenorphine detoxification did not result in significant differences in OWS compared to buprenorphine only but was associated with decreased opioid-positive urine results at follow-up.<xref rid="cit0075" ref-type="bibr">75</xref> Similarly, 450 mg daily pregabalin augmentation of buprenorphine detoxification was not significantly different in SOWS between intervention and placebo augmentation.<xref rid="cit0076" ref-type="bibr">76</xref> A third small trial compared 1600 mg of gabapentin versus 450 mg of pregabalin and placebo. Again, no significant differences were observed in the SOWS.<xref rid="cit0077" ref-type="bibr">77</xref></p><p>Suvorexant, an orexin antagonist used to treat insomnia, has been studied in buprenorphine detoxification tapers. The study doses (20 mg and 40 mg) did not differ from the placebo in the SOWS measurement of OWS. However, suvorexant significantly improved sleep duration, exceeding the American Academy of Sleep Medicine threshold for clinically relevant sleep improvements.<xref rid="cit0078" ref-type="bibr">78</xref></p><p>Dextromethorphan (d-3-methoxy-N-methylmorphine) is a commonly used cough-suppressant. Dextromethorphan exhibits NMDA receptor antagonism, which is similar to memantine listed above, and may help attenuate OWS. In patients receiving clonidine to ameliorate OWS from heroin, dextromethorphan 60 mg (compared with placebo) showed improvements in OOWS scores during the later phase (days 3&#8211;6) of withdrawal. However, this was only revealed during a post-hoc analysis, with no significant difference from the placebo OOWS scores overall.<xref rid="cit0079" ref-type="bibr">79</xref></p><p>Intramuscular olanzapine 10 mg (33 patients), a second-generation antipsychotic, was compared with oral clonidine 0.3 mg (30 patients) in the treatment of OWS in the emergency department. Olanzapine-treated patients received fewer rescue medications and showed greater improvement in COWS; however, no statistical tests were reported. This may be of value when treating OWS in emergency departments that do not have the ability to administer buprenorphine or opioid agonists, or if co-occurring significant agitation is present.<xref rid="cit0080" ref-type="bibr">80</xref></p><p>The role and application of medicinal plants in OWS treatment has also been investigated. One specific plant, <italic toggle="yes">Sophora alopecuroides</italic>, is traditionally used in Iranian folk medicine to treat pain and addiction. The seed extract of <italic toggle="yes">Sophora alopecuroides</italic> (three 400 mg capsules once a day) was found to decrease COWS scores (versus placebo) on days 3 and 8 in patients undergoing opioid withdrawal.<xref rid="cit0081" ref-type="bibr">81</xref> In another study on patients undergoing heroin withdrawal, the seed extract (same dose as above) led to a significant decrease in COWS scores on days 3 and 8 compared to placebo.<xref rid="cit0082" ref-type="bibr">82</xref> The seed extracts also demonstrated a good safety profile.</p><p>Buspirone, a 5-HT1a agonist with D2 antagonist properties and memantine have been investigated to augment buprenorphine tapers for the treatment of OWS. Buspirone 45 mg daily significantly decreased SOWS in combination with buprenorphine versus buprenorphine alone over two weeks of residential treatment for OUD. Buspirone was also associated with improved sleep during the buprenorphine taper.<xref rid="cit0083" ref-type="bibr">83</xref> Memantine at 20 mg dosing, which is lower than other studies investigating the medication, saw no differences in SOWS when combined with buprenorphine and clonidine versus those two medications alone.<xref rid="cit0084" ref-type="bibr">84</xref></p><p>The corticotropin-releasing factor receptor (CRF1) increases the hypothalamus-pituitary axis activity during OWS, and its modulation has been investigated for acute OWS treatment. Pexacerfont, a CRF1 antagonist, was studied for 3 weeks via burst and taper (300 mg, 200 mg, and 100 mg, each daily for 1 week). Cravings and craving-related metrics (eg, temptation severity) were improved with active treatment versus placebo; however, COWS was similar between the groups across the measured time-points.<xref rid="cit0085" ref-type="bibr">85</xref></p><p>Scopolamine is a muscarinic antagonist that is used to treat nausea and vomiting associated with motion sickness. Inpatients with OUD were randomized to receive a methadone taper versus light anesthesia with 0.03&#8211;0.05 mg/kg of scopolamine hydrobromide and 0.6&#8211;1.0 mg/kg of chlorpromazine hydrochloride for 3&#8211;4 days. SOWS was largely stable in the scopolamine group versus an acute 2&#8211;3-day spike in SOWS that was seen in the methadone taper (after the conclusion of dosing). More patients who received scopolamine therapy remained abstinent and in outpatient treatment for 8 weeks compared to those in the methadone taper group. The scopolamine group had significant adverse effects, including respiratory distress, aspiration pneumonia, and pulmonary edema, some of which were life-threatening events.<xref rid="cit0086" ref-type="bibr">86</xref></p></sec><sec id="s0004-s2006"><title>Neurostimulation Interventions</title><p>Neurostimulation in addiction treatment is being extensively studied, primarily for the maintenance of OUD treatment. For OWS management, the most established neurostimulation techniques are mediated by the vagus nerve, either cervically or at the ear, with transcutaneous or percutaneous electrical stimulation. Although the underlying mechanism remains unclear, a plausible pathway exists. Autonomic changes are a hallmark of OWS. The locus coeruleus is the brain&#8217;s principal norepinephrine-producing region and is important in the autonomic nervous system.<xref rid="cit0087" ref-type="bibr">87</xref> In acute opioid withdrawal, locus coeruleus firing rates increase and are associated with OWS.<xref rid="cit0088" ref-type="bibr">88</xref> The locus coeruleus receives input from the vagus nerve via the solitary nucleus.<xref rid="cit0089" ref-type="bibr">89</xref>,<xref rid="cit0090" ref-type="bibr">90</xref> Through use of these neurostimulation devices, there is potential for balance to be regained between the sympathetic and parasympathetic nervous systems.</p><p>While further research is needed to elucidate the underlying treatment mechanisms, the FDA has granted approval for two percutaneous electrical nerve field stimulators (PENFS) for OWS.<xref rid="cit0091" ref-type="bibr">91</xref>,<xref rid="cit0092" ref-type="bibr">92</xref> Both devices require transillumination of the ear to place needle electrodes for periodic stimulation delivery and can be worn for up to five days. A pivotal study by Miranda et al in 2018 led to approval of the Bridge<sup>TM</sup> device. This was an open-label (ie, no sham-control) retrospective study that evaluated 73 outpatients with mild (n = 4) or moderate-to-moderately severe (n = 69) opioid withdrawal. The COWS was assessed up to three times in the initial hour following device placement and again at the 5-day follow-up. At baseline, the mean COWS was 20.1 (SD = 6.1). At 1 h of device use, the mean COWS was 3.1 (SD = 3.4), and 57 (78.1%) individuals with COWS &lt; 4. Thirty-three of 73 (45.2%) individuals were seen at follow-up, with mean COWS of 0.6 (SD not reported). The stated goal was an eventual transition to MOUD, noting that 64 of 73 (88.8%) patients started MOUD; however, the breakdown of MOUD was not presented. They noted that 33 individuals started naltrexone after using the device; however, the number of days following either 1) final opioid use or 2) the final day of the Bridge<sup>TM</sup> device use before naltrexone initiation was not reported. This prevents any hypothesis formation on if this device may reduce precipitated withdrawal symptoms.<xref rid="cit0092" ref-type="bibr">92</xref> Regarding the DyAnsys <italic toggle="yes">Drug Relief</italic><sup>TM</sup> device, there was no readily identifiable data in the literature nor mention within the FDA approval memo regarding specific data that led to FDA device approval.<xref rid="cit0091" ref-type="bibr">91</xref></p><p>A retrospective 5 case series by Buono et al also reported auricular delivery of PENFS for over 5 days. The data presented are sparse; however, only reporting improvements in COWS across study days, alongside daily blood pressure and heart rate. No statistical tests were performed. These cases also existed within a 52-week structured treatment program.<xref rid="cit0093" ref-type="bibr">93</xref> Tirado et al prospectively studied auricular treatment of opioid withdrawal using noninvasive transcutaneous auricular neurostim (tAN). Thirty-one individuals were randomized to receive either 30 minutes of active tAN (n = 16) or 30 minutes of sham treatment (n = 15). There was a more significant reduction in the COWS of the active tAN group than that in the sham group after 30 min of stimulation (reduced by 6.3 compared to 3.7, p = 0.036).<xref rid="cit0094" ref-type="bibr">94</xref></p><p>Two other trials evaluated alternative anatomical locations. Gazi et al investigated transcutaneous cervical vagus nerve stimulation (tcVNS) in individuals with OUD whose last opioid use was at least 8 hours prior. Over two hours, the participants received either four 2-minute active stimulation sessions (n = 10) or four 2-minute sham stimulation sessions (n = 11). The study evaluators considered six scales along with COWS decomposition. While the active group did have significantly improved self-report of subjective cravings, withdrawal, and overall distress, the COWS itself was not significantly different between groups at the 2-hour endpoint.<xref rid="cit0095" ref-type="bibr">95</xref> Meade et al investigated transcutaneous electric acupoint stimulation (TEAS) at acupoints <italic toggle="yes">hegu</italic> and <italic toggle="yes">neiguan</italic> as an adjunctive treatment for opioid detoxification with buprenorphine. Anatomically, electrodes were placed between the first and second metacarpal bones (dorsal and palmar surfaces) of one hand, whereas the other upper limbs had electrodes placed on the median nerve at the forearm (dorsal and palmar surfaces). All the participants received buprenorphine. Twenty-six participants received thrice-daily 30-minute TEAS treatments for four days, while 29 received thrice-daily sham stimulation over four days. Two weeks after discharge, the active TEAS group was less likely to have reported any drug use as compared to the sham group (35% vs 77%, p &lt; 0.05). However, no differences in OWS were observed.<xref rid="cit0096" ref-type="bibr">96</xref></p><p>No studies have used transcranial magnetic stimulation or direct current stimulation for opioid withdrawal. As there is evidence that these interventions combined with MOUD may be beneficial in SUD-related outcomes in maintenance treatment, future research exploring their potential utility in withdrawal management may be warranted.<xref rid="cit0097" ref-type="bibr">97</xref></p></sec></sec><sec id="s0005"><title>Discussion</title><p>Fentanyl exposure has been associated with a reduced likelihood of treatment initiation, worse treatment retention, and increased OWS severity.<xref rid="cit0098" ref-type="bibr">98</xref>,<xref rid="cit0099" ref-type="bibr">99</xref> This review highlights that although IMF has affected the initiation and maintenance of MOUD, many core principles of OWS treatment remain the same. Buprenorphine can be safely and effectively initiated in both observed and unobserved settings, increasing patient autonomy and creating flexibility around timing.<xref rid="cit0100" ref-type="bibr">100</xref> Novel strategies have improved the successful initiation of buprenorphine by reducing the risk of BPOW. A BPOW rate of 1% utilizing newer protocols in fentanyl-positive participants is reassuring, increasing their applicability in the fentanyl era.<xref rid="cit0041" ref-type="bibr">41</xref> As injectable buprenorphine XR becomes more available, more research into accelerated initiation protocols is needed and may help increase successful transition from IMF to buprenorphine. Methadone, an effective treatment for OWS and OUD, has gained momentum in the fentanyl era, given its ease of use and lack of precipitated withdrawal. The deregulation of methadone during the COVID-19 pandemic has improved many patient-centered aspects of MOUD care without increasing methadone-related diversion or overdose deaths. Policies that uncouple methadone treatment from restrictive OTP standards may improve care for OWS and OUD in the fentanyl era. Our review also included quicker and more supportive protocols to transition people with OUD to XR-NTX, allowing practitioners to utilize expedited plans for those most interested in nonopioid strategies. Outside FDA-approved medications for OUD, newer studies on non-opioid pharmacology, such as lofexidine, gabapentin, and suvorexant, have been most helpful in augmenting the initiation of opioid agonists; however, their evidence is limited. Neurostimulation interventions are currently in development, with a few studies showing mild improvement in withdrawal symptoms. Although more research is needed on monotherapy for acute OWS, these devices may be beneficial for patients who choose to transition away from buprenorphine and methadone after establishing OUD remission.</p></sec><sec id="s0006"><title>Conclusion</title><p>There is an urgent need to identify, research, and implement adequate treatments for OWS and OUD in the era of high-potency synthetic opioids such as fentanyl. Buprenorphine and methadone, with or without adjunctive medications, have been used to successfully treat OWS. Research shows that combination treatment and pharmacokinetically informed protocols may reduce OWS severity while reducing the time required for a successful transition to MOUD. Shorter induction protocols allow patients to initiate evidence-based treatment more quickly, reducing the use of illicit or non-prescribed substances.</p></sec></body><back><sec sec-type="COI-statement" id="s0007"><title>Disclosure</title><p>The authors report no conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ahmad</surname><given-names>FBCJ</given-names></string-name>, <string-name name-style="western"><surname>Rossen</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Sutton</surname><given-names>P</given-names></string-name>. <article-title>Provisional drug overdose death counts</article-title>. <source><italic toggle="yes">National Center for Health Statistics</italic></source>. <year>2023</year>.</mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gladden</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Seth</surname><given-names>P</given-names></string-name>. <article-title>Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013-2014</article-title>. <source><italic toggle="yes">MMWR Morb Mortal Wkly Rep</italic></source>. <year>2016</year>;<volume>65</volume>(<issue>33</issue>):<fpage>837</fpage>&#8211;<lpage>843</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm6533a2</pub-id><pub-id pub-id-type="pmid">27560775</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Bekheet</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></string-name>. <article-title>The Evolving Overdose Epidemic: synthetic Opioids and Rising Stimulant-Related Harms</article-title>. <source><italic toggle="yes">Epidemiol Rev</italic></source>. <year>2020</year>;<volume>42</volume>(<issue>1</issue>):<fpage>154</fpage>&#8211;<lpage>166</lpage>. doi:<pub-id pub-id-type="doi">10.1093/epirev/mxaa011</pub-id><pub-id pub-id-type="pmid">33511987</pub-id><pub-id pub-id-type="pmcid">PMC9200066</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jannetto</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Helander</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Garg</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Janis</surname><given-names>GC</given-names></string-name>, <string-name name-style="western"><surname>Goldberger</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ketha</surname><given-names>H</given-names></string-name>. <article-title>The Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union</article-title>. <source><italic toggle="yes">Clin Chem</italic></source>. <year>2019</year>;<volume>65</volume>(<issue>2</issue>):<fpage>242</fpage>&#8211;<lpage>253</lpage>. doi:<pub-id pub-id-type="doi">10.1373/clinchem.2017.281626</pub-id><pub-id pub-id-type="pmid">30305277</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Higginbotham</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Markovic</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Massaly</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Moron</surname><given-names>JA</given-names></string-name>. <article-title>Endogenous opioid systems alterations in pain and opioid use disorder</article-title>. <source><italic toggle="yes">Front Syst Neurosci</italic></source>. <year>2022</year>;<volume>16</volume>:<fpage>1014768</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnsys.2022.1014768</pub-id><pub-id pub-id-type="pmid">36341476</pub-id><pub-id pub-id-type="pmcid">PMC9628214</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Peng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sarkar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>SL</given-names></string-name>. <article-title>Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2012</year>;<volume>124</volume>(<issue>3</issue>):<fpage>223</fpage>&#8211;<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2012.01.013</pub-id><pub-id pub-id-type="pmid">22356890</pub-id><pub-id pub-id-type="pmcid">PMC3366045</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Trescot</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Datta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>H</given-names></string-name>. <article-title>Opioid pharmacology</article-title>. <source><italic toggle="yes">Pain Physician</italic></source>. <year>2008</year>;<volume>11</volume>(<issue>2 Suppl</issue>):<fpage>675</fpage>.<pub-id pub-id-type="pmid">18443637</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Morgan</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Christie</surname><given-names>MJ</given-names></string-name>. <article-title>Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human</article-title>. <source><italic toggle="yes">Br J Pharmacol</italic></source>. <year>2011</year>;<volume>164</volume>(<issue>4</issue>):<fpage>1322</fpage>&#8211;<lpage>1334</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01335.x</pub-id><pub-id pub-id-type="pmid">21434879</pub-id><pub-id pub-id-type="pmcid">PMC3229764</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Williams</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Ingram</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Henderson</surname><given-names>G</given-names></string-name>, et al. <article-title>Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance</article-title>. <source><italic toggle="yes">Pharmacol Rev</italic></source>. <year>2013</year>;<volume>65</volume>(<issue>1</issue>):<fpage>223</fpage>&#8211;<lpage>254</lpage>. doi:<pub-id pub-id-type="doi">10.1124/pr.112.005942</pub-id><pub-id pub-id-type="pmid">23321159</pub-id><pub-id pub-id-type="pmcid">PMC3565916</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pergolizzi</surname><given-names>JV</given-names> Jr</string-name>, <string-name name-style="western"><surname>Raffa</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Rosenblatt</surname><given-names>MH</given-names></string-name>. <article-title>Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management</article-title>. <source><italic toggle="yes">J Clin Pharm Ther</italic></source>. <year>2020</year>;<volume>45</volume>(<issue>5</issue>):<fpage>892</fpage>&#8211;<lpage>903</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jcpt.13114</pub-id><pub-id pub-id-type="pmid">31986228</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>McLellan</surname><given-names>AT</given-names></string-name>. <article-title>Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2016</year>;<volume>374</volume>(<issue>13</issue>):<fpage>1253</fpage>&#8211;<lpage>1263</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMra1507771</pub-id><pub-id pub-id-type="pmid">27028915</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Koob</surname><given-names>GF</given-names></string-name>. <article-title>Anhedonia, Hyperkatifeia, and Negative Reinforcement in Substance Use Disorders</article-title>. <source><italic toggle="yes">Curr Top Behav Neurosci</italic></source>. <year>2022</year>;<volume>58</volume>:<fpage>147</fpage>&#8211;<lpage>165</lpage>. doi:<pub-id pub-id-type="doi">10.1007/7854_2021_288</pub-id><pub-id pub-id-type="pmid">35112332</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wesson</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Ling</surname><given-names>W</given-names></string-name>. <article-title>The Clinical Opiate Withdrawal Scale (COWS)</article-title>. <source><italic toggle="yes">J Psychoactive Drugs</italic></source>. <year>2003</year>;<volume>35</volume>(<issue>2</issue>):<fpage>253</fpage>&#8211;<lpage>259</lpage>. doi:<pub-id pub-id-type="doi">10.1080/02791072.2003.10400007</pub-id><pub-id pub-id-type="pmid">12924748</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Handelsman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cochrane</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Aronson</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Ness</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rubinstein</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Kanof</surname><given-names>PD</given-names></string-name>. <article-title>Two new rating scales for opiate withdrawal</article-title>. <source><italic toggle="yes">Am J Drug Alcohol Abuse</italic></source>. <year>1987</year>;<volume>13</volume>(<issue>3</issue>):<fpage>293</fpage>&#8211;<lpage>308</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00952998709001515</pub-id><pub-id pub-id-type="pmid">3687892</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hall</surname><given-names>OT</given-names></string-name>, <string-name name-style="western"><surname>Entrup</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Farabee</surname><given-names>K</given-names></string-name>, et al. <article-title>The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: a Survey of Syringe Exchange Program Participants</article-title>. <source><italic toggle="yes">Subst Use Misuse</italic></source>. <year>2024</year>;<volume>59</volume>(<issue>2</issue>):<fpage>312</fpage>&#8211;<lpage>315</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10826084.2023.2269571</pub-id><pub-id pub-id-type="pmid">37861246</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Alrawashdeh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Klompas</surname><given-names>M</given-names></string-name>, et al. <article-title>Association of Early Opioid Withdrawal Treatment Strategy and Patient-Directed Discharge Among Hospitalized Patients with Opioid Use Disorder</article-title>. <source><italic toggle="yes">J Gen Intern Med</italic></source>. <year>2023</year>;<volume>38</volume>(<issue>10</issue>):<fpage>2289</fpage>&#8211;<lpage>2297</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-023-08059-w</pub-id><pub-id pub-id-type="pmid">36788169</pub-id><pub-id pub-id-type="pmcid">PMC10406767</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Harris</surname><given-names>M</given-names></string-name>. <article-title>Normalised pain and severe health care delay among people who inject drugs in London: adapting cultural safety principles to promote care</article-title>. <source><italic toggle="yes">Soc Sci Med</italic></source>. <year>2020</year>;<volume>260</volume>:<fpage>113183</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.socscimed.2020.113183</pub-id><pub-id pub-id-type="pmid">32682207</pub-id><pub-id pub-id-type="pmcid">PMC7441308</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kimmel</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Kalesan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Samet</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Walley</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>. <article-title>Against Medical Advice Discharges in Injection and Non-injection Drug Use-associated Infective Endocarditis: a Nationwide Cohort Study</article-title>. <source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2021</year>;<volume>73</volume>(<issue>9</issue>):<fpage>e2484</fpage>&#8211;<lpage>e2492</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciaa1126</pub-id><pub-id pub-id-type="pmid">32756935</pub-id><pub-id pub-id-type="pmcid">PMC8563193</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Simon</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Snow</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wakeman</surname><given-names>S</given-names></string-name>. <article-title>Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study</article-title>. <source><italic toggle="yes">Subst Abus</italic></source>. <year>2020</year>;<volume>41</volume>(<issue>4</issue>):<fpage>519</fpage>&#8211;<lpage>525</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2019.1671942</pub-id><pub-id pub-id-type="pmid">31638862</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Ameli</surname><given-names>O</given-names></string-name>, et al. <article-title>Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder</article-title>. <source><italic toggle="yes">JAMA Network Open</italic></source>. <year>2020</year>;<volume>3</volume>(<issue>2</issue>):<fpage>e1920622</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.20622</pub-id><pub-id pub-id-type="pmid">32022884</pub-id><pub-id pub-id-type="pmcid">PMC11143463</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mattick</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Breen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kimber</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Davoli</surname><given-names>M</given-names></string-name>. <article-title>Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence</article-title>. <source><italic toggle="yes">Cochrane Database Syst Rev</italic></source>. <year>2014</year>;<volume>2014</volume>(<issue>2</issue>):<fpage>CD002207</fpage>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD002207.pub4</pub-id><pub-id pub-id-type="pmid">24500948</pub-id><pub-id pub-id-type="pmcid">PMC10617756</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Stein</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Herman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Conti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname><given-names>G</given-names></string-name>. <article-title>Initiating buprenorphine treatment for opioid use disorder during short-term in-patient &#8216;detoxification&#8217;: a randomized clinical trial</article-title>. <source><italic toggle="yes">Addiction</italic></source>. <year>2020</year>;<volume>115</volume>(<issue>1</issue>):<fpage>82</fpage>&#8211;<lpage>94</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.14737</pub-id><pub-id pub-id-type="pmid">31430414</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Neimark</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tjoa</surname><given-names>C</given-names></string-name>. <article-title>Treating Fentanyl Withdrawal</article-title>. <source><italic toggle="yes">J Behav Health Serv Res</italic></source>. <year>2020</year>;<volume>47</volume>(<issue>4</issue>):<fpage>614</fpage>&#8211;<lpage>615</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11414-020-09710-8</pub-id><pub-id pub-id-type="pmid">32435865</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sue</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tilley</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yocheved</surname><given-names>A</given-names></string-name>. <article-title>A Plea From People Who Use Drugs to Clinicians: new Ways to Initiate Buprenorphine Are Urgently Needed in the Fentanyl Era</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2022</year>;<volume>16</volume>(<issue>4</issue>):<fpage>389</fpage>&#8211;<lpage>391</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000952</pub-id><pub-id pub-id-type="pmid">35020693</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="book"><string-name name-style="western"><surname>Bromley</surname><given-names>LKM</given-names></string-name>, <string-name name-style="western"><surname>Regenstreif</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Srivastava</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wyman</surname><given-names>J</given-names></string-name>. <source><italic toggle="yes">Methadone Treatment for People Who Use Fentanyl: Recommendations</italic></source>. <collab>META: PHI</collab>, editor. <publisher-loc>Toronto, ON</publisher-loc>; <year>2021</year>.</mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Calcaterra</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Bottner</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>M</given-names></string-name>, et al. <article-title>Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: a systematic review of existing guidelines</article-title>. <source><italic toggle="yes">J Hosp Med</italic></source>. <year>2022</year>;<volume>17</volume>(<issue>9</issue>):<fpage>679</fpage>&#8211;<lpage>692</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jhm.12908</pub-id><pub-id pub-id-type="pmid">35880821</pub-id><pub-id pub-id-type="pmcid">PMC9474657</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ciccarone</surname><given-names>D</given-names></string-name>. <article-title>The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis</article-title>. <source><italic toggle="yes">Int J Drug Policy</italic></source>. <year>2019</year>;<volume>71</volume>:<fpage>183</fpage>&#8211;<lpage>188</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2019.01.010</pub-id><pub-id pub-id-type="pmid">30718120</pub-id><pub-id pub-id-type="pmcid">PMC6675668</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Oakley</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hayes</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Lintzeris</surname><given-names>N</given-names></string-name>. <article-title>Managing opioid withdrawal precipitated by buprenorphine with buprenorphine</article-title>. <source><italic toggle="yes">Drug Alcohol Rev</italic></source>. <year>2021</year>;<volume>40</volume>(<issue>4</issue>):<fpage>567</fpage>&#8211;<lpage>571</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dar.13228</pub-id><pub-id pub-id-type="pmid">33480051</pub-id><pub-id pub-id-type="pmcid">PMC8248003</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cisewski</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Koyfman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>B</given-names></string-name>. <article-title>Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting</article-title>. <source><italic toggle="yes">Am J Emerg Med</italic></source>. <year>2019</year>;<volume>37</volume>(<issue>1</issue>):<fpage>143</fpage>&#8211;<lpage>150</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajem.2018.10.013</pub-id><pub-id pub-id-type="pmid">30355476</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Whitley</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Sohler</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Kunins</surname><given-names>HV</given-names></string-name>, et al. <article-title>Factors associated with complicated buprenorphine inductions</article-title>. <source><italic toggle="yes">J Subst Abuse Treat</italic></source>. <year>2010</year>;<volume>39</volume>(<issue>1</issue>):<fpage>51</fpage>&#8211;<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2010.04.001</pub-id><pub-id pub-id-type="pmid">20682186</pub-id><pub-id pub-id-type="pmcid">PMC4755478</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Varshneya</surname><given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Thakrar</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Hobelmann</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Dunn</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Huhn</surname><given-names>AS</given-names></string-name>. <article-title>Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2022</year>;<volume>16</volume>(<issue>4</issue>):<fpage>e265</fpage>&#8211;<lpage>e268</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000922</pub-id><pub-id pub-id-type="pmid">34816821</pub-id><pub-id pub-id-type="pmcid">PMC9124721</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bormann</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Gout</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kijewski</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Lynch</surname><given-names>A</given-names></string-name>. <article-title>Case Report: buprenorphine-precipitated fentanyl withdrawal treated with high-dose buprenorphine</article-title>. <source><italic toggle="yes">F1000Res</italic></source>. <year>2022</year>;<volume>11</volume>:<fpage>487</fpage>. doi:<pub-id pub-id-type="doi">10.12688/f1000research.120821.2</pub-id><pub-id pub-id-type="pmid">37767082</pub-id><pub-id pub-id-type="pmcid">PMC10521070</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Spadaro</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Koyfman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Perrone</surname><given-names>J</given-names></string-name>. <article-title>Buprenorphine precipitated opioid withdrawal: prevention and management in the ED setting</article-title>. <source><italic toggle="yes">Am J Emerg Med</italic></source>. <year>2022</year>;<volume>58</volume>:<fpage>22</fpage>&#8211;<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajem.2022.05.013</pub-id><pub-id pub-id-type="pmid">35623179</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nemlekar</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dave</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Chaudhari</surname><given-names>F</given-names></string-name>. <article-title>Opioid withdrawal and its stabilization on sublingual buprenorphine in intravenous drug users: a South Gujarat Perspective</article-title>. <source><italic toggle="yes">j Arch Psychiatry Psychother</italic></source>. <year>2020</year>;<volume>22</volume>(<issue>1</issue>):<fpage>63</fpage>&#8211;<lpage>69</lpage>. doi:<pub-id pub-id-type="doi">10.12740/app/109265</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hammig</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kemter</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Strasser</surname><given-names>J</given-names></string-name>, et al. <article-title>Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method</article-title>. <source><italic toggle="yes">Subst Abuse Rehabil</italic></source>. <year>2016</year>;<volume>7</volume>:<fpage>99</fpage>&#8211;<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.2147/SAR.S109919</pub-id><pub-id pub-id-type="pmid">27499655</pub-id><pub-id pub-id-type="pmcid">PMC4959756</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cohen</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Weimer</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Levander</surname><given-names>XA</given-names></string-name>, <string-name name-style="western"><surname>Peckham</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Tetrault</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Morford</surname><given-names>KL</given-names></string-name>. <article-title>Low Dose Initiation of Buprenorphine: a Narrative Review and Practical Approach</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2022</year>;<volume>16</volume>(<issue>4</issue>):<fpage>399</fpage>&#8211;<lpage>406</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000945</pub-id><pub-id pub-id-type="pmid">34954746</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Baumgartner</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Salmo</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Liss</surname><given-names>D</given-names></string-name>, et al. <article-title>Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study</article-title>. <source><italic toggle="yes">Clin Toxicol</italic></source>. <year>2022</year>;<volume>60</volume>(<issue>6</issue>):<fpage>688</fpage>&#8211;<lpage>693</lpage>. doi:<pub-id pub-id-type="doi">10.1080/15563650.2022.2028802</pub-id><pub-id pub-id-type="pmid">35048759</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Webster</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hjelmstrom</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sumner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gunderson</surname><given-names>EW</given-names></string-name>. <article-title>Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: a randomized trial</article-title>. <source><italic toggle="yes">J Addict Dis</italic></source>. <year>2016</year>;<volume>35</volume>(<issue>4</issue>):<fpage>325</fpage>&#8211;<lpage>338</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10550887.2016.1195608</pub-id><pub-id pub-id-type="pmid">27267785</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Herring</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Vosooghi</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Luftig</surname><given-names>J</given-names></string-name>, et al. <article-title>High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder</article-title>. <source><italic toggle="yes">JAMA Network Open</italic></source>. <year>2021</year>;<volume>4</volume>(<issue>7</issue>):<fpage>e2117128</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.17128</pub-id><pub-id pub-id-type="pmid">34264326</pub-id><pub-id pub-id-type="pmcid">PMC8283555</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hassman</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Strafford</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shinde</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Boyett</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dobbins</surname><given-names>RL</given-names></string-name>. <article-title>Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection</article-title>. <source><italic toggle="yes">Am J Drug Alcohol Abuse</italic></source>. <year>2023</year>;<volume>49</volume>(<issue>1</issue>):<fpage>43</fpage>&#8211;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00952990.2022.2106574</pub-id><pub-id pub-id-type="pmid">36001871</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>D&#8217;Onofrio</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hawk</surname><given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Perrone</surname><given-names>J</given-names></string-name>, et al. <article-title>Incidence of Precipitated Withdrawal During a Multisite Emergency Department-Initiated Buprenorphine Clinical Trial in the Era of Fentanyl</article-title>. <source><italic toggle="yes">JAMA Network Open</italic></source>. <year>2023</year>;<volume>6</volume>(<issue>3</issue>):<fpage>e236108</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.6108</pub-id><pub-id pub-id-type="pmid">36995717</pub-id><pub-id pub-id-type="pmcid">PMC10064247</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ahmadi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jahromi</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Ghahremani</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>London</surname><given-names>ED</given-names></string-name>. <article-title>Single high-dose buprenorphine for opioid craving during withdrawal</article-title>. <source><italic toggle="yes">Trials</italic></source>. <year>2018</year>;<volume>19</volume>(<issue>1</issue>):<fpage>675</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13063-018-3055-z</pub-id><pub-id pub-id-type="pmid">30526648</pub-id><pub-id pub-id-type="pmcid">PMC6288888</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mariani</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Mahony</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Iqbal</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>SX</given-names></string-name>, <string-name name-style="western"><surname>Naqvi</surname><given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>FR</given-names></string-name>. <article-title>Case Series: rapid Induction Onto Long Acting Buprenorphine Injection for High Potency Synthetic Opioid Users</article-title>. <source><italic toggle="yes">Am J Addict</italic></source>. <year>2020</year>;<volume>29</volume>(<issue>4</issue>):<fpage>345</fpage>&#8211;<lpage>348</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ajad.13018</pub-id><pub-id pub-id-type="pmid">32167629</pub-id><pub-id pub-id-type="pmcid">PMC7383940</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Su</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Crossa</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hoffman</surname><given-names>RS</given-names></string-name>. <article-title>Low dose intramuscular methadone for acute mild to moderate opioid withdrawal syndrome</article-title>. <source><italic toggle="yes">Am J Emerg Med</italic></source>. <year>2018</year>;<volume>36</volume>(<issue>11</issue>):<fpage>1951</fpage>&#8211;<lpage>1956</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajem.2018.02.019</pub-id><pub-id pub-id-type="pmid">29544903</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chalabianloo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Fadnes</surname><given-names>LT</given-names></string-name>, <string-name name-style="western"><surname>Hoiseth</surname><given-names>G</given-names></string-name>, et al. <article-title>Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway</article-title>. <source><italic toggle="yes">Subst Abuse Treat Prev Policy</italic></source>. <year>2021</year>;<volume>16</volume>(<issue>1</issue>):<fpage>39</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13011-021-00367-w</pub-id><pub-id pub-id-type="pmid">33941217</pub-id><pub-id pub-id-type="pmcid">PMC8091668</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Laks</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kehoe</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Farrell</surname><given-names>NM</given-names></string-name>, et al. <article-title>Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule</article-title>. <source><italic toggle="yes">Addict Sci Clin Pract</italic></source>. <year>2021</year>;<volume>16</volume>(<issue>1</issue>):<fpage>73</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13722-021-00279-x</pub-id><pub-id pub-id-type="pmid">34961554</pub-id><pub-id pub-id-type="pmcid">PMC8712102</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Taylor</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Laks</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Christine</surname><given-names>PJ</given-names></string-name>, et al. <article-title>Bridge clinic implementation of &#8220;72-hour rule&#8221; methadone for opioid withdrawal management: impact on opioid treatment program linkage and retention in care</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2022</year>;<volume>236</volume>:<fpage>109497</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2022.109497</pub-id><pub-id pub-id-type="pmid">35607834</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Enns</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Krebs</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Whitehurst</surname><given-names>DGT</given-names></string-name>, et al. <article-title>Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2023</year>;<volume>247</volume>:<fpage>109893</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2023.109893</pub-id><pub-id pub-id-type="pmid">37120920</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Panwala</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Joudrey</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kowalski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bach</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Amram</surname><given-names>O</given-names></string-name>. <article-title>Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: a narrative review</article-title>. <source><italic toggle="yes">J Subst Use Addict Treat</italic></source>. <year>2023</year>;<volume>152</volume>:<fpage>209086</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.josat.2023.209086</pub-id><pub-id pub-id-type="pmid">37270103</pub-id><pub-id pub-id-type="pmcid">PMC10232933</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="webpage"><collab>GovTrack</collab>. <article-title>S. 644: modernizing Opioid Treatment Access Act</article-title>. <comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.govtrack.us/congress/bills/118/s644" ext-link-type="uri">https://www.govtrack.us/congress/bills/118/s644</ext-link>. <date-in-citation>Accessed <month>February</month><day>1</day>, 2024</date-in-citation>.</mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gauthier</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Eibl</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Marsh</surname><given-names>DC</given-names></string-name>. <article-title>Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2018</year>;<volume>191</volume>:<fpage>1</fpage>&#8211;<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.04.029</pub-id><pub-id pub-id-type="pmid">30064001</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Strang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hickman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bird</surname><given-names>SM</given-names></string-name>. <article-title>Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2010</year>;<volume>341</volume>:<fpage>c4851</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.c4851</pub-id><pub-id pub-id-type="pmid">20847018</pub-id><pub-id pub-id-type="pmcid">PMC2941573</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Simon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vincent</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Coulter</surname><given-names>A</given-names></string-name>, et al. <article-title>The Methadone Manifesto: treatment Experiences and Policy Recommendations From Methadone Patient Activists</article-title>. <source><italic toggle="yes">Am J Public Health</italic></source>. <year>2022</year>;<volume>112</volume>(<issue>S2</issue>):<fpage>S117</fpage>&#8211;<lpage>S122</lpage>. doi:<pub-id pub-id-type="doi">10.2105/AJPH.2021.306665</pub-id><pub-id pub-id-type="pmid">35349312</pub-id><pub-id pub-id-type="pmcid">PMC8965191</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Compton</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></string-name>. <article-title>Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs</article-title>. <source><italic toggle="yes">JAMA Psychiatry</italic></source>. <year>2022</year>;<volume>79</volume>(<issue>9</issue>):<fpage>932</fpage>&#8211;<lpage>934</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.1776</pub-id><pub-id pub-id-type="pmid">35830198</pub-id><pub-id pub-id-type="pmcid">PMC9280608</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="webpage"><collab>Administration SAa MHS</collab>. <article-title>Methadone take-home flexibilities extension guidance</article-title>. <year>2021</year>. <comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines/methadone-guidance" ext-link-type="uri">https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines/methadone-guidance</ext-link>. <date-in-citation>Accessed <month>February</month><day>1</day>, 2024</date-in-citation>.</mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Krawczyk</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Rivera</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dooling</surname><given-names>BCE</given-names></string-name>. <article-title>Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy</article-title>. <source><italic toggle="yes">Lancet Public Health</italic></source>. <year>2023</year>;<volume>8</volume>(<issue>3</issue>):<fpage>e238</fpage>&#8211;<lpage>e246</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2468-2667(23)00023-3</pub-id><pub-id pub-id-type="pmid">36841564</pub-id><pub-id pub-id-type="pmcid">PMC9949855</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Socias</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>H</given-names></string-name>, et al. <article-title>Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): protocol for a non-inferiority randomized clinical trial</article-title>. <source><italic toggle="yes">Contemp Clin Trials</italic></source>. <year>2020</year>;<volume>91</volume>:<fpage>105993</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cct.2020.105993</pub-id><pub-id pub-id-type="pmid">32194251</pub-id><pub-id pub-id-type="pmcid">PMC7919741</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ferri</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Minozzi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Amato</surname><given-names>L</given-names></string-name>. <article-title>Slow-release oral morphine as maintenance therapy for opioid dependence</article-title>. <source><italic toggle="yes">Cochrane Database Syst Rev</italic></source>. <year>2013</year>;<volume>2</volume>(<issue>6</issue>):<fpage>CD009879</fpage>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD009879.pub2</pub-id><pub-id pub-id-type="pmcid">PMC11976517</pub-id><pub-id pub-id-type="pmid">23740540</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zarghami</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Masoum</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Shiran</surname><given-names>MR</given-names></string-name>. <article-title>Tramadol versus methadone for treatment of opiate withdrawal: a double-blind, randomized, clinical trial</article-title>. <source><italic toggle="yes">J Addict Dis</italic></source>. <year>2012</year>;<volume>31</volume>(<issue>2</issue>):<fpage>112</fpage>&#8211;<lpage>117</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10550887.2012.665728</pub-id><pub-id pub-id-type="pmid">22540433</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="book"><string-name name-style="western"><surname>Dean</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kane</surname><given-names>M</given-names></string-name>, et al. <part-title>Tramadol Therapy and CYP2D6 Genotype</part-title>. In: <string-name name-style="western"><surname>Pratt</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Pirmohamed</surname><given-names>M</given-names></string-name>, editors. <source><italic toggle="yes">Medical Genetics Summaries [Internet]</italic></source>. <publisher-name>National Center for Biotechnology Information</publisher-name>; <year>2021</year>.<pub-id pub-id-type="pmid">28520365</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kleinman</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>. <article-title>Treating Opioid Withdrawal in the Hospital: a Role for Short-Acting Opioids</article-title>. <source><italic toggle="yes">Ann Intern Med</italic></source>. <year>2022</year>;<volume>175</volume>(<issue>2</issue>):<fpage>283</fpage>&#8211;<lpage>284</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M21-3968</pub-id><pub-id pub-id-type="pmid">34807718</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Thakrar</surname><given-names>AP</given-names></string-name>. <article-title>Short-Acting Opioids for Hospitalized Patients With Opioid Use Disorder</article-title>. <source><italic toggle="yes">JAMA Intern Med</italic></source>. <year>2022</year>;<volume>182</volume>(<issue>3</issue>):<fpage>247</fpage>&#8211;<lpage>248</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamainternmed.2021.8111</pub-id><pub-id pub-id-type="pmid">35099508</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lee</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Nunes</surname><given-names>EV</given-names> Jr</string-name>, <string-name name-style="western"><surname>Novo</surname><given-names>P</given-names></string-name>, et al. <article-title>Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2018</year>;<volume>391</volume>(<issue>10118</issue>):<fpage>309</fpage>&#8211;<lpage>318</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(17)32812-X</pub-id><pub-id pub-id-type="pmid">29150198</pub-id><pub-id pub-id-type="pmcid">PMC5806119</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rudolf</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Plawman</surname><given-names>A</given-names></string-name>, et al. <article-title>A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment</article-title>. <source><italic toggle="yes">Am J Drug Alcohol Abuse</italic></source>. <year>2018</year>;<volume>44</volume>(<issue>3</issue>):<fpage>302</fpage>&#8211;<lpage>309</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00952990.2017.1334209</pub-id><pub-id pub-id-type="pmid">28795846</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mannelli</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>LT</given-names></string-name>, <string-name name-style="western"><surname>Peindl</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Swartz</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Woody</surname><given-names>GE</given-names></string-name>. <article-title>Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2014</year>;<volume>138</volume>:<fpage>83</fpage>&#8211;<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2014.02.002</pub-id><pub-id pub-id-type="pmid">24602363</pub-id><pub-id pub-id-type="pmcid">PMC4017322</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mannelli</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Swartz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>LT</given-names></string-name>. <article-title>Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone</article-title>. <source><italic toggle="yes">Am J Addict</italic></source>. <year>2018</year>;<volume>27</volume>(<issue>6</issue>):<fpage>471</fpage>&#8211;<lpage>476</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ajad.12763</pub-id><pub-id pub-id-type="pmid">30028058</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sullivan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bisaga</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pavlicova</surname><given-names>M</given-names></string-name>, et al. <article-title>Long-Acting Injectable Naltrexone Induction: a Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine</article-title>. <source><italic toggle="yes">Am J Psychiatry</italic></source>. <year>2017</year>;<volume>174</volume>(<issue>5</issue>):<fpage>459</fpage>&#8211;<lpage>467</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajp.2016.16050548</pub-id><pub-id pub-id-type="pmid">28068780</pub-id><pub-id pub-id-type="pmcid">PMC5411308</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bisaga</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mannelli</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>M</given-names></string-name>, et al. <article-title>Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: a Phase 3 randomized trial</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2018</year>;<volume>187</volume>:<fpage>171</fpage>&#8211;<lpage>178</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.02.023</pub-id><pub-id pub-id-type="pmid">29674251</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Safari</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mottaghi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Malek</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Salimi</surname><given-names>A</given-names></string-name>. <article-title>Effect of ultra-rapid opiate detoxification on withdrawal syndrome</article-title>. <source><italic toggle="yes">J Addict Dis</italic></source>. <year>2010</year>;<volume>29</volume>(<issue>4</issue>):<fpage>449</fpage>&#8211;<lpage>454</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10550887.2010.509278</pub-id><pub-id pub-id-type="pmid">20924880</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bisaga</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sullivan</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>WY</given-names></string-name>, et al. <article-title>A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2011</year>;<volume>119</volume>(<issue>1&#8211;2</issue>):<fpage>e23</fpage>&#8211;<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2011.05.019</pub-id><pub-id pub-id-type="pmid">21715107</pub-id><pub-id pub-id-type="pmcid">PMC3199033</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bisaga</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sullivan</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Glass</surname><given-names>A</given-names></string-name>, et al. <article-title>A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence</article-title>. <source><italic toggle="yes">J Subst Abuse Treat</italic></source>. <year>2014</year>;<volume>46</volume>(<issue>5</issue>):<fpage>546</fpage>&#8211;<lpage>552</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2014.01.005</pub-id><pub-id pub-id-type="pmid">24560438</pub-id><pub-id pub-id-type="pmcid">PMC4007510</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gorodetzky</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Saxon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Gullo</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Biswas</surname><given-names>K</given-names></string-name>. <article-title>A Phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2017</year>;<volume>176</volume>:<fpage>79</fpage>&#8211;<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.02.020</pub-id><pub-id pub-id-type="pmid">28527421</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fishman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tirado</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Alam</surname><given-names>D</given-names></string-name>, et al. <article-title>Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: a Randomized Controlled Clinical Trial</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2019</year>;<volume>13</volume>(<issue>3</issue>):<fpage>169</fpage>&#8211;<lpage>176</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000474</pub-id><pub-id pub-id-type="pmid">30531234</pub-id><pub-id pub-id-type="pmcid">PMC6541556</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Guo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Manning</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: a double-blind randomized clinical trial in Singapore</article-title>. <source><italic toggle="yes">J Subst Abuse Treat</italic></source>. <year>2018</year>;<volume>91</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2018.04.012</pub-id><pub-id pub-id-type="pmid">29910009</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sanders</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Mancino</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Gentry</surname><given-names>WB</given-names></string-name>, et al. <article-title>Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure</article-title>. <source><italic toggle="yes">Exp Clin Psychopharmacol</italic></source>. <year>2013</year>;<volume>21</volume>(<issue>4</issue>):<fpage>294</fpage>&#8211;<lpage>302</lpage>. doi:<pub-id pub-id-type="doi">10.1037/a0033724</pub-id><pub-id pub-id-type="pmid">23855333</pub-id><pub-id pub-id-type="pmcid">PMC3972066</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kheirabadi</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Moazeni</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Salehi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mahaki</surname><given-names>B</given-names></string-name>. <article-title>Pregabalin Does Not Reduce Opioid Withdrawal Symptoms: a Randomized Controlled Trial</article-title>. <source><italic toggle="yes">Addictive Disorders Their Treatment</italic></source>. <year>2019</year>;<volume>18</volume>(<issue>4</issue>):<fpage>205</fpage>&#8211;<lpage>211</lpage>. doi:<pub-id pub-id-type="doi">10.1097/adt.0000000000000166</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kheirabadi</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Salehi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bahrami</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maracy</surname><given-names>MR</given-names></string-name>. <article-title>Gabapentin, Pregabalin, and Placebo in Reducing Opioid Withdrawal Symptoms in Opioid-dependent Individuals: a Randomized-controlled Trial</article-title>. <source><italic toggle="yes">Addictive Disorders Their Treatment</italic></source>. <year>2018</year>;<volume>17</volume>(<issue>2</issue>):<fpage>55</fpage>&#8211;<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.1097/adt.0000000000000127</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Huhn</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Finan</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>Gamaldo</surname><given-names>CE</given-names></string-name>, et al. <article-title>Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper</article-title>. <source><italic toggle="yes">Sci Transl Med</italic></source>. <year>2022</year>;<volume>14</volume>(<issue>650</issue>):<fpage>eabn8238</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.abn8238</pub-id><pub-id pub-id-type="pmid">35731889</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lin</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>CH</given-names></string-name>. <article-title>A double-blind, placebo-controlled trial of dextromethorphan combined with clonidine in the treatment of heroin withdrawal</article-title>. <source><italic toggle="yes">J Clin Psychopharmacol</italic></source>. <year>2014</year>;<volume>34</volume>(<issue>4</issue>):<fpage>508</fpage>&#8211;<lpage>512</lpage>. doi:<pub-id pub-id-type="doi">10.1097/JCP.0000000000000144</pub-id><pub-id pub-id-type="pmid">24875077</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Klein</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Cole</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Driver</surname><given-names>BE</given-names></string-name>, et al. <article-title>An open-label randomized trial of intramuscular olanzapine versus oral clonidine for symptomatic treatment of opioid withdrawal in the emergency department</article-title>. <source><italic toggle="yes">Clin Toxicol</italic></source>. <year>2019</year>;<volume>57</volume>(<issue>8</issue>):<fpage>697</fpage>&#8211;<lpage>702</lpage>. doi:<pub-id pub-id-type="doi">10.1080/15563650.2018.1547828</pub-id><pub-id pub-id-type="pmid">30712404</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kianbakht</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hajiaghaee</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Akhondzadeh</surname><given-names>S</given-names></string-name>. <article-title>Efficacy and safety of <italic toggle="yes">Sophora alopecuroides</italic> var. <italic toggle="yes">alopecuroides</italic> seed extract for opioid detoxification: a randomized, double-blind, and placebo-controlled clinical trial</article-title>. <source><italic toggle="yes">Phytother Res</italic></source>. <year>2020</year>;<volume>34</volume>(<issue>5</issue>):<fpage>1108</fpage>&#8211;<lpage>1113</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ptr.6578</pub-id><pub-id pub-id-type="pmid">31793731</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hashem-Dabaghian</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kianbakht</surname><given-names>S</given-names></string-name>. <article-title>A randomized controlled trial on the seeds of Sophora alopecuroides var. alopecuroides for the treatment of acute heroin withdrawal syndrome</article-title>. <source><italic toggle="yes">Complement Ther Clin Pract</italic></source>. <year>2023</year>;<volume>51</volume>:<fpage>101740</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ctcp.2023.101740</pub-id><pub-id pub-id-type="pmid">36827871</pub-id></mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bergeria</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Antoine</surname><given-names>D</given-names></string-name>, et al. <article-title>A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal</article-title>. <source><italic toggle="yes">Exp Clin Psychopharmacol</italic></source>. <year>2023</year>;<volume>31</volume>(<issue>1</issue>):<fpage>194</fpage>&#8211;<lpage>203</lpage>. doi:<pub-id pub-id-type="doi">10.1037/pha0000550</pub-id><pub-id pub-id-type="pmid">35266779</pub-id><pub-id pub-id-type="pmcid">PMC11000212</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kheirabadi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Najafian</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Khodadadi</surname><given-names>F</given-names></string-name>. <article-title>The Effect of Adding Memantine to Clonidine in Reducing Withdrawal Symptoms in Opioid-Dependent Patients: a Double-Blind Randomized Controlled Trial</article-title>. <source><italic toggle="yes">J Clin Psychopharmacol</italic></source>. <year>2021</year>;<volume>41</volume>(<issue>6</issue>):<fpage>644</fpage>&#8211;<lpage>649</lpage>. doi:<pub-id pub-id-type="doi">10.1097/JCP.0000000000001466</pub-id><pub-id pub-id-type="pmid">34559090</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Morabbi</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Razaghi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Moazen-Zadeh</surname><given-names>E</given-names></string-name>, et al. <article-title>Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial</article-title>. <source><italic toggle="yes">Int Clin Psychopharmacol</italic></source>. <year>2018</year>;<volume>33</volume>(<issue>2</issue>):<fpage>111</fpage>&#8211;<lpage>119</lpage>. doi:<pub-id pub-id-type="doi">10.1097/YIC.0000000000000200</pub-id><pub-id pub-id-type="pmid">29064909</pub-id></mixed-citation></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>W</given-names></string-name>. <article-title>Scopolamine detoxification technique for heroin dependence: a randomized trial</article-title>. <source><italic toggle="yes">CNS Drugs</italic></source>. <year>2013</year>;<volume>27</volume>(<issue>12</issue>):<fpage>1093</fpage>&#8211;<lpage>1102</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40263-013-0111-9</pub-id><pub-id pub-id-type="pmid">24092568</pub-id></mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Samuels</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Szabadi</surname><given-names>E</given-names></string-name>. <article-title>Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation</article-title>. <source><italic toggle="yes">Curr Neuropharmacol</italic></source>. <year>2008</year>;<volume>6</volume>(<issue>3</issue>):<fpage>235</fpage>&#8211;<lpage>253</lpage>. doi:<pub-id pub-id-type="doi">10.2174/157015908785777229</pub-id><pub-id pub-id-type="pmid">19506723</pub-id><pub-id pub-id-type="pmcid">PMC2687936</pub-id></mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rasmussen</surname><given-names>K</given-names></string-name>. <article-title>The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal</article-title>. <source><italic toggle="yes">Neuropsychopharmacology</italic></source>. <year>1995</year>;<volume>13</volume>(<issue>4</issue>):<fpage>295</fpage>&#8211;<lpage>300</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0893-133X(95)00082-O</pub-id><pub-id pub-id-type="pmid">8747753</pub-id></mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Farrand</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jacquemet</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Verner</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Owens</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Beaumont</surname><given-names>E</given-names></string-name>. <article-title>Vagus nerve stimulation parameters evoke differential neuronal responses in the locus coeruleus</article-title>. <source><italic toggle="yes">Physiological Reports</italic></source>. <year>2023</year>;<volume>11</volume>(<issue>5</issue>):<fpage>e15633</fpage>. doi:<pub-id pub-id-type="doi">10.14814/phy2.15633</pub-id><pub-id pub-id-type="pmid">36905173</pub-id><pub-id pub-id-type="pmcid">PMC10006695</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Fornai</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ruffoli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Giorgi</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Paparelli</surname><given-names>A</given-names></string-name>. <article-title>The role of locus coeruleus in the antiepileptic activity induced by vagus nerve stimulation</article-title>. <source><italic toggle="yes">Eur J Neurosci</italic></source>. <year>2011</year>;<volume>33</volume>(<issue>12</issue>):<fpage>2169</fpage>&#8211;<lpage>2178</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1460-9568.2011.07707.x</pub-id><pub-id pub-id-type="pmid">21535457</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="report"><string-name name-style="western"><surname>U.S. Food &amp; Drug Administration</surname></string-name>, <source>Drug Relief - Percutaneous Nerve Stimulator for Opioid Withdrawal</source><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/cdrh_docs/pdf17/K173861.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/cdrh_docs/pdf17/K173861.pdf</ext-link><year>2018</year><date-in-citation>Accessed <day>20</day><month>11</month> 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Miranda</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Taca</surname><given-names>A</given-names></string-name>. <article-title>Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment</article-title>. <source><italic toggle="yes">Am J Drug Alcohol Abuse</italic></source>. <year>2018</year>;<volume>44</volume>(<issue>1</issue>):<fpage>56</fpage>&#8211;<lpage>63</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00952990.2017.1295459</pub-id><pub-id pub-id-type="pmid">28301217</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Buono</surname><given-names>FD</given-names></string-name>, <string-name name-style="western"><surname>Pickering</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Berlepsch</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Halligan</surname><given-names>S</given-names></string-name>. <article-title>Percutaneous electrical nerve field stimulation to reduce clinical opiate withdrawal: a case series</article-title>. <source><italic toggle="yes">J Subst Use</italic></source>. <year>2022</year>;<volume>27</volume>(<issue>5</issue>):<fpage>501</fpage>&#8211;<lpage>504</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14659891.2021.1961894</pub-id></mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tirado</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Washburn</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Covalin</surname><given-names>A</given-names></string-name>, et al. <article-title>Delivering transcutaneous auricular neurostimulation (tAN) to improve symptoms associated with opioid withdrawal: results from a prospective clinical trial</article-title>. <source><italic toggle="yes">Bioelectronic Medicine</italic></source>. <year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>12</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s42234-022-00095-x</pub-id><pub-id pub-id-type="pmid">35978394</pub-id><pub-id pub-id-type="pmcid">PMC9385243</pub-id></mixed-citation></ref><ref id="cit0095"><label>95.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gazi</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Harrison</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Lambert</surname><given-names>TP</given-names></string-name>, et al. <article-title>Transcutaneous cervical vagus nerve stimulation reduces behavioral and physiological manifestations of withdrawal in patients with opioid use disorder: a double-blind, randomized, sham-controlled pilot study</article-title>. <source><italic toggle="yes">Brain Stimul</italic></source>. <year>2022</year>;<volume>15</volume>(<issue>5</issue>):<fpage>1206</fpage>&#8211;<lpage>1214</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.brs.2022.08.017</pub-id><pub-id pub-id-type="pmid">36041704</pub-id><pub-id pub-id-type="pmcid">PMC9588751</pub-id></mixed-citation></ref><ref id="cit0096"><label>96.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Meade</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Lukas</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>McDonald</surname><given-names>LJ</given-names></string-name>, et al. <article-title>A randomized trial of transcutaneous electric acupoint stimulation as adjunctive treatment for opioid detoxification</article-title>. <source><italic toggle="yes">J Subst Abuse Treat</italic></source>. <year>2010</year>;<volume>38</volume>(<issue>1</issue>):<fpage>12</fpage>&#8211;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2009.05.010</pub-id><pub-id pub-id-type="pmid">19574017</pub-id><pub-id pub-id-type="pmcid">PMC2789908</pub-id></mixed-citation></ref><ref id="cit0097"><label>97.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bormann</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Oesterle</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Arndt</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Karpyak</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Croarkin</surname><given-names>PE</given-names></string-name>. <article-title>Systematic review and meta-analysis: combining transcranial magnetic stimulation or direct current stimulation with pharmacotherapy for treatment of substance use disorders</article-title>. <source><italic toggle="yes">Am J Addict</italic></source>. <year>2024</year>. doi:<pub-id pub-id-type="doi">10.1111/ajad.13517</pub-id><pub-id pub-id-type="pmid">38273429</pub-id></mixed-citation></ref><ref id="cit0098"><label>98.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Socias</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Le Foll</surname><given-names>B</given-names></string-name>, et al. <article-title>Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial</article-title>. <source><italic toggle="yes">Addiction</italic></source>. <year>2022</year>;<volume>117</volume>(<issue>10</issue>):<fpage>2662</fpage>&#8211;<lpage>2672</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.15954</pub-id><pub-id pub-id-type="pmid">35712892</pub-id><pub-id pub-id-type="pmcid">PMC9969999</pub-id></mixed-citation></ref><ref id="cit0099"><label>99.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Thakrar</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Faude</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Perrone</surname><given-names>J</given-names></string-name>, et al. <article-title>Association of Urine Fentanyl Concentration With Severity of Opioid Withdrawal Among Patients Presenting to the Emergency Department</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2023</year>;<volume>17</volume>(<issue>4</issue>):<fpage>447</fpage>&#8211;<lpage>453</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000001155</pub-id><pub-id pub-id-type="pmid">37579106</pub-id><pub-id pub-id-type="pmcid">PMC10440418</pub-id></mixed-citation></ref><ref id="cit0100"><label>100.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Amass</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pukeleviciene</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Subata</surname><given-names>E</given-names></string-name>, et al. <article-title>A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals</article-title>. <source><italic toggle="yes">Addiction</italic></source>. <year>2012</year>;<volume>107</volume>(<issue>1</issue>):<fpage>142</fpage>&#8211;<lpage>151</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1360-0443.2011.03577.x</pub-id><pub-id pub-id-type="pmid">21749526</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>